疏肝—健脾—疏肝健脾方与肝郁脾虚证相关的研究
摘要
方证相关是中医辨证论治和方剂学的的核心内容。方剂的疗效不仅与药物的组成有关,还与其所主病证紧密相关。方与证之间关联程度的大小直接影响方剂的效用。虽然近年围绕方证相关的研究取得一些进展,但是鲜有研究能为方证相关提供系统的实证依据。本研究基于上述背景,以不同方剂作用于同一病证模型为切入点,通过观察比较药物干预模型后的效应差异,揭示方证相关的科学内涵。
本研究首先以肝郁脾虚证的中医病因学说、临床研究及与其相关的现代疾病的生理病理变化为背景,采用慢性束缚+过度疲劳+饮食失节法复制肝郁脾虚证动物模型,通过观察神经-免疫-内分泌系统的多个指标,探查肝郁脾虚证动物模型的生物学基础。在此基础上,选择疏肝、健脾、疏肝健脾的代表方—柴胡疏肝散、四君子汤、柴疏四君汤作用于肝郁脾虚证动物模型,比较三方的效应异同,探讨三方与肝郁脾虚证动物模型之间的关联性及生物学基础。最后运用基因芯片技术探查肝郁脾虚证模型及柴疏四君汤干预模型后的大鼠肝脏全基因表达,从分子层面为科学理解方证相关提供依据。
全文分为文献综述和实验研究两大部分,文献综述主要包括肝郁脾虚证的临床及实验研究,柴胡疏肝散、四君子汤、柴疏四君汤的临床及实验研究。实验研究主要从免疫系统、甲状腺轴、HPA轴、消化系统、血液系统、肝脏差异基因表达等方面探查肝郁脾虚证大鼠模型的变化,比较观察柴胡疏肝散、四君子汤、柴疏四君汤对肝郁脾虚证大鼠模型作用后的效应异同。
研究一、肝郁脾虚证大鼠模型的免疫系统变化及相关方剂的作用
方法：将大鼠随机分为正常组模型组,柴胡疏肝散组、四君子汤组、柴疏四君汤组,每组12只。模型组大鼠采用慢性束缚应激+过度疲劳+饮食失节法造模,将大鼠于每天上午8：00置于束缚盒中限制3小时,下午2：00置于盛有温水(22±1℃)的大塑料桶中游泳10分钟。隔日喂食(隔日禁食,隔日足量给食),连续4周.正常对照组不加任何刺激,自然饲养。于造模第15d,中药各组大鼠分别按柴胡疏肝散4.2g／kg·d、四君子汤4.53g／kg·d、柴疏四君汤4.27g／kg·d,灌胃,1次／d,连续14d；模型组和对照组分别给予等量蒸馏水。于第29d取材,用放免试剂盒检测IL-2和L-6,用MTT法检测T淋巴细胞增殖率。
结果：模型组大鼠血清IL-2、IL-6及均T淋巴细胞增殖率显著降低。柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的血清IL-2均呈显著性升高；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠血清IL-6均见不同程度升高,其中柴胡疏肝散和柴疏四君汤组呈显著性升高；柴胡疏肝散、四君子汤和柴疏四君汤三组T淋巴细胞增殖率均呈不同程度升高,其中柴疏四君汤组呈显著性升高。
结论：肝郁脾虚证模型大鼠免疫功能低下；柴疏四君汤在提高肝郁脾虚证模型大鼠免疫功能方面优于柴胡疏肝散和四君子汤。
研究二、肝郁脾虚证大鼠模型甲状腺变化及相关方剂的作用
方法：造模方法及药物干预同前。用放免试剂盒检测T3、T4、TRH、TSH。
结果：模型组大鼠血清TRH、TSH、T3、T4均见显著降低。柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的血清T3、T4均呈显著性升高；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠血清TRH、TSH均见不同程度升高,其中柴疏四君汤组呈显著性升高。
结论：肝郁脾虚证模型大鼠甲状腺功能低下；柴疏四君汤在提高肝郁脾虚证模型大鼠甲状腺功能方面优于柴胡疏肝散和四君子汤。
研究三、肝郁脾虚证大鼠模型HPA轴变化及相关方剂的作用
方法：造模方法及药物干预同前。用放免试剂盒检测浆CRH、ACTH、COR和下丘脑CRH
结果：模型组大鼠血浆CRH、COR及下丘脑CRH均见显著升高,血浆ACTH显著降低。柴胡疏肝散组、四君子汤组、柴疏四君汤组大鼠血浆中CRH含量均有不同程度降低,但差异均无显著性意义；柴胡疏肝散组、四君子汤组、柴疏四君汤组大血浆中ACTH含量均显著增加；柴胡疏肝散组、四君子汤组、柴疏四君汤组大鼠血浆中COR含量均不同程度降低,其中柴疏四君汤组显著降低；柴胡疏肝散组、四君子汤组、柴疏四君汤组大鼠下丘脑CRH含量均不同程度的降低,其中柴疏四君汤组和柴胡疏肝散组显著降低。
结论：肝郁脾虚证模型大鼠HPA轴功能异常；柴疏四君汤在恢复肝郁脾虚证模型大鼠HPA轴功能异常方面优于柴胡疏肝散和四君子汤。
研究四、肝郁脾虚证大鼠模型消化系统的变化及相关方剂的作用
方法：造模方法及药物干预同前。用放免试剂盒检测MTL、SS,对溴苯胺法检测D-木糖排泄率,分光光度法检测胃蛋白酶,用酶组织化学法观测肝脏SDH和G-6-PD。
结果：模型组大鼠血浆MTL、SS及胃蛋白酶均见显著升高,D-木糖排泄率显著降低,肝脏SDH、G-6-PD均见显著升高。柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的血清MTL均呈显著性降低；柴胡疏肝散、柴疏四君汤二组大鼠血清SS均见不同程度降低,四君子汤组显著升高；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的D-木糖排泄率均呈不同程度升高,其中柴疏四君汤组和四君子汤组均呈显著升高；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的胃蛋白酶均呈不同程度降低,其中柴疏四君汤组显著降低。柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠SDH均呈显著性降低；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠G-6-PD均见不同程度升高,其中柴疏四君汤组呈显著性升高。
结论：肝郁脾虚证模型大鼠消化功能及肝酶表达异常；柴疏四君汤在恢复消化功能及肝酶方面优于柴胡疏肝散和四君子汤。
研究五、肝郁脾虚证大鼠模型血液系统的变化及相关方剂的作用
方法：造模方法及药物干预同前。用MVIS-2035全自动血液流变分析仪检测全血流变,血液全自动分析仪检测血常规,CA—500全自动血凝分析仪检测凝血功能。
结果：模型组大鼠的红细胞压积指数显著升高,红细胞聚集指数显著降低(P<0.001),红细胞变形指数无显著性差异,150/s、38/s、10/s、5/s切变率下的全血粘度均显著升高,150/s、38/s、10/s、5/s切变率下的还原粘度无显著变化,血常规(WBC、RBC、HGB、PLT)、凝血功能(APTT、PT、PTA、Fib)均无显著变化。柴胡疏肝散组、四君子汤组和柴疏四君汤组的红细胞压积、聚集指数、变形指数、全血还原粘度、WBC、RBC、HGB、PLT、凝血功能均无显著变化；四君子汤可显著降低各切变率下全血粘度,柴胡疏肝散能显著降低高切下全血粘度,其余均无显著性变化。
结论：肝郁脾虚证模型大鼠全血流变异常,血常规及凝血功能指标均无明显改变；三方对血液常规和凝血功能指标无明显影响,四君子汤可改善肝郁脾虚模型大鼠血流变的异常,柴胡疏肝散次之,柴疏四君汤对其无明显作用。
研究六肝郁脾虚证大鼠模型肝脏的差异基因探查及柴疏四君汤的作用
方法：造模方法及药物干预同前。无菌条件下剖取肝脏,进行脾脏RNA的提取、样品RNA荧光标记、杂交与清洗、芯片扫描、图像采集与数据分析；主要利用http://www. genome.ad. jp/kegg/中的基因库对差异基因进行功能检索。
结果：模型组的差异表达基因有59条,其中上调基因有27条,下调基因有32条；其中涉及到已知功能基因有Scdl、Dbp、Upp2、Slc28a2、Sds、Hpn、Gldc、Tm7sf2、Gcat、Btg3、Lin7a、Zfp354a、Rgs2、Duspl1、Ldha。柴疏四君汤作用肝郁脾虚证模型差异表达基因25条,其中上调基因有13条,下调基因有12条；涉及到已知功能基因有Hhex、Myc、Hmgcr、Ccl7、Bubl。
结论：肝郁脾虚证存在基因异常表达,涉及脂类代谢、糖代谢等多个方面。柴疏四君汤作用于肝郁脾虚证模型的差异基因主要涉及细胞周期和糖代谢方面。提示多个基因的异常表达可能是中医肝郁脾虚证的分子基础,而柴疏四君汤对肝郁脾虚证多个相关基因发挥调节作用。
本课题采用慢性束缚+过度疲劳+饮食失节法复制肝郁脾虚证动物模型,比较观察了柴胡疏肝散、四君子汤和柴疏四君汤三方对该肝郁脾虚证模型的作用异同。结果发现,肝郁脾虚证大鼠模型存在胃肠功能、神经内分泌,血流变及肝酶等多系统的异常改变；柴疏四君汤在调节肝郁脾虚模型免疫系统、甲状腺轴、HPA轴、消化系统、肝酶方面优于柴胡疏肝散和四君子汤,并且影响模型的多个差异基因的表达。结果表明,柴疏四君汤与肝郁脾虚证具有较高的相关性。该课题为揭示中医肝郁脾虚证及方证相关的现代内涵提供了一定的客观依据。
"Correlation between Formula and Syndrome" is the core content of in the diagnosis and treatment based on differentiation of symptoms and signs and formula-ology. The function and usage of formula not only havecorrelation with medical compatibility but also compatible with the syndrome which it will have effect on, that is the main effect of the formula depends on a considerable extent on the pathology and the role of targets of medicalcompatibility. Although the progress has been made about "Correlation between Formula and Syndrome",less scientific evidence is provided for it. Based on the background, the research is began with different formulae's action on the same model.The scientific meaning of Correlation between Formula and Syndrome is revealed through comparing and observing the effect of three formulae's action on the same model.
The dissertation was to explore the rats'syndrome model of stagnation of live anddeficiency of spleen (GYPX) which was made by the method of compound causes of diseaseaccording to the TCM's theory of attack, clinical manifestation and some physiological and pathological characteristics of some modern diseases about this syndrome and to acquire the Chinese syndrome and some biological characteristics of this model through observing manytargets about the nerve-endocrine-immunity system; On these achievements, we observed and compared similarities and differences of action of, SJZT and CSSJT which had therespective function of soothing liver, invigorating spleen andsoothing liver and invigorating spleen on GYPX model and probed into the associatedcharacter and partial modern biological basis of these associate between the effectiveness ofthe three prescriptions and the model of disease and syndrome on the condition of different prescription on the same syndrome. Finally, we explored genes expression of the model and CSSJT influencing it by applying microarray technology, and deeply approachedmolecular mechanism of the model and cssjt influencing it.
This thesis is divided into two main parts:literature review and experimental research. literature review include clinnic and experimental research of GYPX, CHSGS, SJZT and CSSJT. The change of immune system, HPTA, HPA, digest system and blood circulation made by CHSGS, SJZT and CSSJT and Gene expression profiles associated with preliminary exploration of the syndromes of GYPX deficiency of rat model and study of the effect of CSSJT on the model. Research 1:the change of immune system of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (lml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. Interleukin-2 (IL-2) and interleukin-6(IL-6) in serum and spleen T lymphocyte proliferation rate of groups were observed by the method of RIA.
Results:IL-2, IL-6, spleen T lymphocyte proliferation rate of model group decreased significantly. IL-2 of CHSGS,SJZT,CSSJT increased significa-ntly. IL-6 of CHSGS, SJZT, CSSJT increased in varying degrees, and CHSGS and CSSJT were ignificant. Spleen T lymphocyte proliferation rate of CHS-GS, SJZT, CSSJT increased in varying degrees,and CSSJT was significant. Conclusion:The abnormal changes turned up in immune system. CSSJTwas better than CHSGS and SJZT in adjusting these abnormal changes.
Research 2:the change of throid system of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (lml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. T3, T4, TRH and TSH of groups were determined by the method of RIA.
Results:T3,T4,TRH and TSH of model group were significantly decreased. T3 and T4 in serum of CHSGS, SJZT and CSSJT groups were significantly increased. TRH and TSH in serum of CSSJT group markedly increased.
Conclusion:The abnormal changes turned up in thyroid system. CSSJT was better than CHSGS and SJZT in adjusting these abnormal changes.
Research 3:the change of HPA of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (1ml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. CRH, ACTH, COR, CRH in the hypothalamus were determined.by the method of RIA.
Results:CRH,COR in plasma and CRH in the hypothalamus of model group increased significantly and ACTH in plasma of model group decreased significantly. CRH in plasma of CHSGS, SJZT, CSSJT decreased in varying degrees,not significantly. ACTH in plasma of CHSGS, SJZT, CSSJT increased significantly. COR in plasma of CHSGS, SJZT, CSSJT decreased in varying degrees,and chsjt was significantly. CRH in the hypothalamus of CHSGS, SJZT, CSSJT decreased in varying degrees,and CSSJT and chsgs were sig-nificantly.
Conclusion:The abnormal changes turned up in HPA. CSSJT was better than CHSGS and SJZT in adjusting these abnormal changes.
Research 4:the change of digest system of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (1ml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. MTL and SS in plasma by the method of RIA, D-xyloseexcretion rate in urine by the method of adjacent aminotoluene, pepsin by the method of spectrophotometer,and SDH and G-6-PD in liver by the method of NBT were determined.
Results:MTL and SS in plasma, pepsin, and SDH and G-6-PD in liver of model group increased significantly. D-xyloseexcretion rate in urine of model group decreased significantly. MTL in plasma of CHSGS, SJZT, CSSJT group decreased significantly. SS in plasma of CHSGS and CSSJT group decreased in varying degrees,and SJZT group increased significantly. D-xyloseexc-retion rate in urine of CHSGS, SJZT, CSSJT group increased in varying degrees, and SJZT and CSSJT were significant. Pepsin of CHSGS, SJZT, CSSJT group decreased in varying degrees, and CSSJT was significant. SDH in liver of CHSGS, SJZT, CSSJT group decreased significantly. G-6-PD in liver of CHS-GS, SJZT, CSSJT group increased significantly,and CSSJT was significant. Conclusion:The abnormal changes turned up in digest system and SDH and G-6-PD in liver. CSSJTwas better than CHSGS and SJZT in adjusting these abnormal changes.
Research 5:the change of blood circulation in liver of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (1ml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. Hemorheology measured by blood viscosimeter, blood routine test by automatic blood cell counter, blood coagulation function by Automatic coagulation analyzer were determined.
Results:The index of erythrocyte aggregation decreased, hematocrit increased significantly and the index of erythrocyte deformability had no change. The whole blood viscosity under different shear rates of model group's rats increased significantly and reduced viscosity had no change. Blood routine test and blood coagulation function had no change. The index of erythrocyte aggregation, hematocrit, index of erythrocyte deformabi-lity, reduced viscosity under different shear rates, blood routine test (WBC、RBC、HGB、PLT) and blood coagulation (APTT、PT、PTA、Fib) of CHSGS,SJZT,CSSJT group had no change. The whole blood viscosity under different shear rates of SJZT group decreased significantly. The whole blood viscosity under higher shear rates of CHSGS group decreased sign-ificantly.
Conclusion:The abnormal changes turned up in blood circulation. CSSJTwas better than CHSGS and SJZT in adjusting these abnormal changes. Research 6:Exploration of gene expression on the syndromes of GYPX and the effects of cssjt.
Methods:The rats were assigned to 3 groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CSSJT group,12 rats in each group. The rats of CSSJT group were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual. The rats of CSSJT group were orally administrated with CSSJT (lml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. We extract RNA from liver, and tag RNA by fluores-cence, hybridizate and cleanse, scan chip, collect picture and analyze data; At last we inquest functions of obstained different genes by gene bank of http://www. genome.ad. jp/kegg/.
Results:There are 59 differentially expressed genes in model group, genes, among them,27 genes are upregulation and 32 downregulation, referring to inquest known functional genes as followed:Scdl、Dbp、Upp2、 Slc28a2、Sds、Hpn、Gldc、Tm7sf2、Gcat、Btg3、Lin7a、Zfp354a、Rgs2、Duspll、Ldha; CSSJT group has 25 differentially expressed genes, among them 13 are upregulation and 12 aredownregulation; referring to inquest known functional genes as followed:Hhex、Myc、Hmgcr、Ccl7、Bubl.
Conclusion:The model of the syndromes of GYPX exists abnormal expression of part genes, known functional genes of involved in metabolism of glucose and metabolism of fatty; CSSJT has generally regulate to genes expression of GYPX, the main known functional genes mainly influence metabolism of glucose and cell circle. The results cue that abnormal expression of several genes is possibly molecular foundation of the syndromes of GYPX, however related formula of treating the syndromes of GYPX have complicate regulate to many genes including abnormal expression genes of the synd-romes of GYPX.
The change of the function of stomach and intestine, NEI network, blood circulation, SDH and G-6-PD in liver had been observed in GYPX model made bythe method of chronic astricting, excess fatigue and out of constant diet on ratsBased on the result, we observed the different action of CHSGS, SJZT, and CSSJT on the GYPX model made by the method of chronic astricting, excess fatigue and out of constant diet on rats and discovered that the function of CSSJT was better than that of CHSGS and SJZT in the way of adjusting abnormal change of immune system, HPTA, HPA,digest system and blood circulation. The syudy had provided objective evidence for cor-relation between prescription and syndrome.
本研究首先以肝郁脾虚证的中医病因学说、临床研究及与其相关的现代疾病的生理病理变化为背景,采用慢性束缚+过度疲劳+饮食失节法复制肝郁脾虚证动物模型,通过观察神经-免疫-内分泌系统的多个指标,探查肝郁脾虚证动物模型的生物学基础。在此基础上,选择疏肝、健脾、疏肝健脾的代表方—柴胡疏肝散、四君子汤、柴疏四君汤作用于肝郁脾虚证动物模型,比较三方的效应异同,探讨三方与肝郁脾虚证动物模型之间的关联性及生物学基础。最后运用基因芯片技术探查肝郁脾虚证模型及柴疏四君汤干预模型后的大鼠肝脏全基因表达,从分子层面为科学理解方证相关提供依据。
全文分为文献综述和实验研究两大部分,文献综述主要包括肝郁脾虚证的临床及实验研究,柴胡疏肝散、四君子汤、柴疏四君汤的临床及实验研究。实验研究主要从免疫系统、甲状腺轴、HPA轴、消化系统、血液系统、肝脏差异基因表达等方面探查肝郁脾虚证大鼠模型的变化,比较观察柴胡疏肝散、四君子汤、柴疏四君汤对肝郁脾虚证大鼠模型作用后的效应异同。
研究一、肝郁脾虚证大鼠模型的免疫系统变化及相关方剂的作用
方法：将大鼠随机分为正常组模型组,柴胡疏肝散组、四君子汤组、柴疏四君汤组,每组12只。模型组大鼠采用慢性束缚应激+过度疲劳+饮食失节法造模,将大鼠于每天上午8：00置于束缚盒中限制3小时,下午2：00置于盛有温水(22±1℃)的大塑料桶中游泳10分钟。隔日喂食(隔日禁食,隔日足量给食),连续4周.正常对照组不加任何刺激,自然饲养。于造模第15d,中药各组大鼠分别按柴胡疏肝散4.2g／kg·d、四君子汤4.53g／kg·d、柴疏四君汤4.27g／kg·d,灌胃,1次／d,连续14d；模型组和对照组分别给予等量蒸馏水。于第29d取材,用放免试剂盒检测IL-2和L-6,用MTT法检测T淋巴细胞增殖率。
结果：模型组大鼠血清IL-2、IL-6及均T淋巴细胞增殖率显著降低。柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的血清IL-2均呈显著性升高；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠血清IL-6均见不同程度升高,其中柴胡疏肝散和柴疏四君汤组呈显著性升高；柴胡疏肝散、四君子汤和柴疏四君汤三组T淋巴细胞增殖率均呈不同程度升高,其中柴疏四君汤组呈显著性升高。
结论：肝郁脾虚证模型大鼠免疫功能低下；柴疏四君汤在提高肝郁脾虚证模型大鼠免疫功能方面优于柴胡疏肝散和四君子汤。
研究二、肝郁脾虚证大鼠模型甲状腺变化及相关方剂的作用
方法：造模方法及药物干预同前。用放免试剂盒检测T3、T4、TRH、TSH。
结果：模型组大鼠血清TRH、TSH、T3、T4均见显著降低。柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的血清T3、T4均呈显著性升高；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠血清TRH、TSH均见不同程度升高,其中柴疏四君汤组呈显著性升高。
结论：肝郁脾虚证模型大鼠甲状腺功能低下；柴疏四君汤在提高肝郁脾虚证模型大鼠甲状腺功能方面优于柴胡疏肝散和四君子汤。
研究三、肝郁脾虚证大鼠模型HPA轴变化及相关方剂的作用
方法：造模方法及药物干预同前。用放免试剂盒检测浆CRH、ACTH、COR和下丘脑CRH
结果：模型组大鼠血浆CRH、COR及下丘脑CRH均见显著升高,血浆ACTH显著降低。柴胡疏肝散组、四君子汤组、柴疏四君汤组大鼠血浆中CRH含量均有不同程度降低,但差异均无显著性意义；柴胡疏肝散组、四君子汤组、柴疏四君汤组大血浆中ACTH含量均显著增加；柴胡疏肝散组、四君子汤组、柴疏四君汤组大鼠血浆中COR含量均不同程度降低,其中柴疏四君汤组显著降低；柴胡疏肝散组、四君子汤组、柴疏四君汤组大鼠下丘脑CRH含量均不同程度的降低,其中柴疏四君汤组和柴胡疏肝散组显著降低。
结论：肝郁脾虚证模型大鼠HPA轴功能异常；柴疏四君汤在恢复肝郁脾虚证模型大鼠HPA轴功能异常方面优于柴胡疏肝散和四君子汤。
研究四、肝郁脾虚证大鼠模型消化系统的变化及相关方剂的作用
方法：造模方法及药物干预同前。用放免试剂盒检测MTL、SS,对溴苯胺法检测D-木糖排泄率,分光光度法检测胃蛋白酶,用酶组织化学法观测肝脏SDH和G-6-PD。
结果：模型组大鼠血浆MTL、SS及胃蛋白酶均见显著升高,D-木糖排泄率显著降低,肝脏SDH、G-6-PD均见显著升高。柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的血清MTL均呈显著性降低；柴胡疏肝散、柴疏四君汤二组大鼠血清SS均见不同程度降低,四君子汤组显著升高；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的D-木糖排泄率均呈不同程度升高,其中柴疏四君汤组和四君子汤组均呈显著升高；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠的胃蛋白酶均呈不同程度降低,其中柴疏四君汤组显著降低。柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠SDH均呈显著性降低；柴胡疏肝散、四君子汤、柴疏四君汤三组大鼠G-6-PD均见不同程度升高,其中柴疏四君汤组呈显著性升高。
结论：肝郁脾虚证模型大鼠消化功能及肝酶表达异常；柴疏四君汤在恢复消化功能及肝酶方面优于柴胡疏肝散和四君子汤。
研究五、肝郁脾虚证大鼠模型血液系统的变化及相关方剂的作用
方法：造模方法及药物干预同前。用MVIS-2035全自动血液流变分析仪检测全血流变,血液全自动分析仪检测血常规,CA—500全自动血凝分析仪检测凝血功能。
结果：模型组大鼠的红细胞压积指数显著升高,红细胞聚集指数显著降低(P<0.001),红细胞变形指数无显著性差异,150/s、38/s、10/s、5/s切变率下的全血粘度均显著升高,150/s、38/s、10/s、5/s切变率下的还原粘度无显著变化,血常规(WBC、RBC、HGB、PLT)、凝血功能(APTT、PT、PTA、Fib)均无显著变化。柴胡疏肝散组、四君子汤组和柴疏四君汤组的红细胞压积、聚集指数、变形指数、全血还原粘度、WBC、RBC、HGB、PLT、凝血功能均无显著变化；四君子汤可显著降低各切变率下全血粘度,柴胡疏肝散能显著降低高切下全血粘度,其余均无显著性变化。
结论：肝郁脾虚证模型大鼠全血流变异常,血常规及凝血功能指标均无明显改变；三方对血液常规和凝血功能指标无明显影响,四君子汤可改善肝郁脾虚模型大鼠血流变的异常,柴胡疏肝散次之,柴疏四君汤对其无明显作用。
研究六肝郁脾虚证大鼠模型肝脏的差异基因探查及柴疏四君汤的作用
方法：造模方法及药物干预同前。无菌条件下剖取肝脏,进行脾脏RNA的提取、样品RNA荧光标记、杂交与清洗、芯片扫描、图像采集与数据分析；主要利用http://www. genome.ad. jp/kegg/中的基因库对差异基因进行功能检索。
结果：模型组的差异表达基因有59条,其中上调基因有27条,下调基因有32条；其中涉及到已知功能基因有Scdl、Dbp、Upp2、Slc28a2、Sds、Hpn、Gldc、Tm7sf2、Gcat、Btg3、Lin7a、Zfp354a、Rgs2、Duspl1、Ldha。柴疏四君汤作用肝郁脾虚证模型差异表达基因25条,其中上调基因有13条,下调基因有12条；涉及到已知功能基因有Hhex、Myc、Hmgcr、Ccl7、Bubl。
结论：肝郁脾虚证存在基因异常表达,涉及脂类代谢、糖代谢等多个方面。柴疏四君汤作用于肝郁脾虚证模型的差异基因主要涉及细胞周期和糖代谢方面。提示多个基因的异常表达可能是中医肝郁脾虚证的分子基础,而柴疏四君汤对肝郁脾虚证多个相关基因发挥调节作用。
本课题采用慢性束缚+过度疲劳+饮食失节法复制肝郁脾虚证动物模型,比较观察了柴胡疏肝散、四君子汤和柴疏四君汤三方对该肝郁脾虚证模型的作用异同。结果发现,肝郁脾虚证大鼠模型存在胃肠功能、神经内分泌,血流变及肝酶等多系统的异常改变；柴疏四君汤在调节肝郁脾虚模型免疫系统、甲状腺轴、HPA轴、消化系统、肝酶方面优于柴胡疏肝散和四君子汤,并且影响模型的多个差异基因的表达。结果表明,柴疏四君汤与肝郁脾虚证具有较高的相关性。该课题为揭示中医肝郁脾虚证及方证相关的现代内涵提供了一定的客观依据。
"Correlation between Formula and Syndrome" is the core content of in the diagnosis and treatment based on differentiation of symptoms and signs and formula-ology. The function and usage of formula not only havecorrelation with medical compatibility but also compatible with the syndrome which it will have effect on, that is the main effect of the formula depends on a considerable extent on the pathology and the role of targets of medicalcompatibility. Although the progress has been made about "Correlation between Formula and Syndrome",less scientific evidence is provided for it. Based on the background, the research is began with different formulae's action on the same model.The scientific meaning of Correlation between Formula and Syndrome is revealed through comparing and observing the effect of three formulae's action on the same model.
The dissertation was to explore the rats'syndrome model of stagnation of live anddeficiency of spleen (GYPX) which was made by the method of compound causes of diseaseaccording to the TCM's theory of attack, clinical manifestation and some physiological and pathological characteristics of some modern diseases about this syndrome and to acquire the Chinese syndrome and some biological characteristics of this model through observing manytargets about the nerve-endocrine-immunity system; On these achievements, we observed and compared similarities and differences of action of, SJZT and CSSJT which had therespective function of soothing liver, invigorating spleen andsoothing liver and invigorating spleen on GYPX model and probed into the associatedcharacter and partial modern biological basis of these associate between the effectiveness ofthe three prescriptions and the model of disease and syndrome on the condition of different prescription on the same syndrome. Finally, we explored genes expression of the model and CSSJT influencing it by applying microarray technology, and deeply approachedmolecular mechanism of the model and cssjt influencing it.
This thesis is divided into two main parts:literature review and experimental research. literature review include clinnic and experimental research of GYPX, CHSGS, SJZT and CSSJT. The change of immune system, HPTA, HPA, digest system and blood circulation made by CHSGS, SJZT and CSSJT and Gene expression profiles associated with preliminary exploration of the syndromes of GYPX deficiency of rat model and study of the effect of CSSJT on the model. Research 1:the change of immune system of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (lml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. Interleukin-2 (IL-2) and interleukin-6(IL-6) in serum and spleen T lymphocyte proliferation rate of groups were observed by the method of RIA.
Results:IL-2, IL-6, spleen T lymphocyte proliferation rate of model group decreased significantly. IL-2 of CHSGS,SJZT,CSSJT increased significa-ntly. IL-6 of CHSGS, SJZT, CSSJT increased in varying degrees, and CHSGS and CSSJT were ignificant. Spleen T lymphocyte proliferation rate of CHS-GS, SJZT, CSSJT increased in varying degrees,and CSSJT was significant. Conclusion:The abnormal changes turned up in immune system. CSSJTwas better than CHSGS and SJZT in adjusting these abnormal changes.
Research 2:the change of throid system of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (lml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. T3, T4, TRH and TSH of groups were determined by the method of RIA.
Results:T3,T4,TRH and TSH of model group were significantly decreased. T3 and T4 in serum of CHSGS, SJZT and CSSJT groups were significantly increased. TRH and TSH in serum of CSSJT group markedly increased.
Conclusion:The abnormal changes turned up in thyroid system. CSSJT was better than CHSGS and SJZT in adjusting these abnormal changes.
Research 3:the change of HPA of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (1ml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. CRH, ACTH, COR, CRH in the hypothalamus were determined.by the method of RIA.
Results:CRH,COR in plasma and CRH in the hypothalamus of model group increased significantly and ACTH in plasma of model group decreased significantly. CRH in plasma of CHSGS, SJZT, CSSJT decreased in varying degrees,not significantly. ACTH in plasma of CHSGS, SJZT, CSSJT increased significantly. COR in plasma of CHSGS, SJZT, CSSJT decreased in varying degrees,and chsjt was significantly. CRH in the hypothalamus of CHSGS, SJZT, CSSJT decreased in varying degrees,and CSSJT and chsgs were sig-nificantly.
Conclusion:The abnormal changes turned up in HPA. CSSJT was better than CHSGS and SJZT in adjusting these abnormal changes.
Research 4:the change of digest system of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (1ml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. MTL and SS in plasma by the method of RIA, D-xyloseexcretion rate in urine by the method of adjacent aminotoluene, pepsin by the method of spectrophotometer,and SDH and G-6-PD in liver by the method of NBT were determined.
Results:MTL and SS in plasma, pepsin, and SDH and G-6-PD in liver of model group increased significantly. D-xyloseexcretion rate in urine of model group decreased significantly. MTL in plasma of CHSGS, SJZT, CSSJT group decreased significantly. SS in plasma of CHSGS and CSSJT group decreased in varying degrees,and SJZT group increased significantly. D-xyloseexc-retion rate in urine of CHSGS, SJZT, CSSJT group increased in varying degrees, and SJZT and CSSJT were significant. Pepsin of CHSGS, SJZT, CSSJT group decreased in varying degrees, and CSSJT was significant. SDH in liver of CHSGS, SJZT, CSSJT group decreased significantly. G-6-PD in liver of CHS-GS, SJZT, CSSJT group increased significantly,and CSSJT was significant. Conclusion:The abnormal changes turned up in digest system and SDH and G-6-PD in liver. CSSJTwas better than CHSGS and SJZT in adjusting these abnormal changes.
Research 5:the change of blood circulation in liver of the model of GYPX syndrome and the effect of CHSGS, SJZT and CSSJT on the model of GYPX syndrome
Methods:The rats were assigned to five groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CHSGS group, SJZT group and CSSJT group,12 rats in each group. The rats of latter four groups were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual.
The rats of three medical groups were orally administrated with CHSGS, SJZT, CSSJT (1ml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. Hemorheology measured by blood viscosimeter, blood routine test by automatic blood cell counter, blood coagulation function by Automatic coagulation analyzer were determined.
Results:The index of erythrocyte aggregation decreased, hematocrit increased significantly and the index of erythrocyte deformability had no change. The whole blood viscosity under different shear rates of model group's rats increased significantly and reduced viscosity had no change. Blood routine test and blood coagulation function had no change. The index of erythrocyte aggregation, hematocrit, index of erythrocyte deformabi-lity, reduced viscosity under different shear rates, blood routine test (WBC、RBC、HGB、PLT) and blood coagulation (APTT、PT、PTA、Fib) of CHSGS,SJZT,CSSJT group had no change. The whole blood viscosity under different shear rates of SJZT group decreased significantly. The whole blood viscosity under higher shear rates of CHSGS group decreased sign-ificantly.
Conclusion:The abnormal changes turned up in blood circulation. CSSJTwas better than CHSGS and SJZT in adjusting these abnormal changes. Research 6:Exploration of gene expression on the syndromes of GYPX and the effects of cssjt.
Methods:The rats were assigned to 3 groups randomly:normal group, model group of stagnation of liver and deficiency of spleen, CSSJT group,12 rats in each group. The rats of CSSJT group were administrated by chronic restricting and excess fatigue with out constant diet for four weeks and normal group rats were fed as usual. The rats of CSSJT group were orally administrated with CSSJT (lml·100g-1·d-1) respectively from the 15th day to the end and rats of normal and model groups were given equal volume of distilled water. We extract RNA from liver, and tag RNA by fluores-cence, hybridizate and cleanse, scan chip, collect picture and analyze data; At last we inquest functions of obstained different genes by gene bank of http://www. genome.ad. jp/kegg/.
Results:There are 59 differentially expressed genes in model group, genes, among them,27 genes are upregulation and 32 downregulation, referring to inquest known functional genes as followed:Scdl、Dbp、Upp2、 Slc28a2、Sds、Hpn、Gldc、Tm7sf2、Gcat、Btg3、Lin7a、Zfp354a、Rgs2、Duspll、Ldha; CSSJT group has 25 differentially expressed genes, among them 13 are upregulation and 12 aredownregulation; referring to inquest known functional genes as followed:Hhex、Myc、Hmgcr、Ccl7、Bubl.
Conclusion:The model of the syndromes of GYPX exists abnormal expression of part genes, known functional genes of involved in metabolism of glucose and metabolism of fatty; CSSJT has generally regulate to genes expression of GYPX, the main known functional genes mainly influence metabolism of glucose and cell circle. The results cue that abnormal expression of several genes is possibly molecular foundation of the syndromes of GYPX, however related formula of treating the syndromes of GYPX have complicate regulate to many genes including abnormal expression genes of the synd-romes of GYPX.
The change of the function of stomach and intestine, NEI network, blood circulation, SDH and G-6-PD in liver had been observed in GYPX model made bythe method of chronic astricting, excess fatigue and out of constant diet on ratsBased on the result, we observed the different action of CHSGS, SJZT, and CSSJT on the GYPX model made by the method of chronic astricting, excess fatigue and out of constant diet on rats and discovered that the function of CSSJT was better than that of CHSGS and SJZT in the way of adjusting abnormal change of immune system, HPTA, HPA,digest system and blood circulation. The syudy had provided objective evidence for cor-relation between prescription and syndrome.
引文
[1]陈国林.潘其匣,赵玉秋.等.中医肝病证候临床辨证标准的研究.中国医药学报[J].1990,6(1)66-73
[2]吴圣贤,方素钦,王映辉,等.中医肝郁脾虚证症状分布和特征专家问卷调查研究[J].北京中医药大学学报,2007,30(12)：854-856.
[3]金益强,胡随瑜,张翔,等.中医不同证候血浆去甲肾上腺素和肾上腺素及植物神经功能的研究[J].中西医结合杂志,1998,18(11)：655-657.
[4]肖桂林,金益强,鄢东红,等.单纯脾气虚证与肝郁脾虚证内在差别的实验研究[J].江西中医学院学报,2000,12(1)：35.
[5]李家邦,王勇华.肝郁脾虚证患者植物神经功能障碍的特征[J].湖南医学院学报,1985,10(1)：63-66.
[6]杨兴中,刘伟英.慢性乙型肝炎中医辨证分型与客观检测指标关系的探讨[J].山西中医,1991,7(2)：9-11.
[7]鲍逊,杨珍珠,范纯武,等.慢性肝病中医辨证分型的生化和免疫学基础的初步探讨[J].中医杂志,1982,23(7)：516-519.
[8]龚远明,张杜郎,张仲苓.病毒性肝炎的中医分型与免疫关系[J].陕西中医,1993,14(7)：328-329.
[9]楼孝惠,陈智,黄茵,等.慢性乙型肝炎中医证型与IL-2,IL-10,IL-12,IFN-r水平的关系初探[J].中西医结合肝病杂志,2001,11(5)：282.
[10]周虎,周萍,俞庆福.慢性病毒性肝炎T淋巴细胞亚群、免疫球蛋白变化与中医证候关系探讨[J].江西中医学院学报,2001,13(2)：49.
[11]郑洪新,李德新,赵明山,等.肝郁脾虚证消化性溃疡的神经免疫学研[J].中国中医基础医学杂志,1996,2(3)：27.
[12]杨英,关茂会,李艳荣,等.慢性肝炎患者血清T3、T4变化与中医辨证分型的联系[J].中西医结合杂志,1986,6(6)：341.
[13]谭行华,肖真,杨克彬,等.慢性肝炎中医分型与内分泌激素的关系[J].中西医结合杂志,1995,15(10)：604-605.
[14]金益强,刘璜英,李学文.227例肝郁脾虚证患者小肠吸收功能障碍的分析[J].湖南医学院学报,1985,10(1)：38-39.
[15]张俊富,崔丽安.慢性肝炎及肝硬化辨证分型与血清肝纤维化指标的关系[J].中西医结合肝病杂志,1995,5(4)：10-11.
[16]杨兴中,刘伟英.慢性乙型肝炎中医辨证分型与客观检测指标关系的探[J].山西中医,1991,7(2)：9-11.
[17]陈礼华,陈燕,杨帆,等.慢性肝炎的辨证分型与血清肝纤维化指标的关系[J].中西医结合肝病杂志,1997,7(3)：165-166.
[18]任平,黄熙,李双庆,等.脾气虚、肝郁脾虚及胃实热证患者阿魏酸药代动力学特征比较[J].中西医结合学报,2006,4(2)：147-151.
[19]邝元亮,颜文明.肝郁脾虚证血液流变性之初步研究[J].湖南中医学院学报,1989,9(2)：101.
[20]陈国祯.肝郁脾虚证的本质探讨[J].中西医结合杂志,1985,5(12)：732-735.
[21]顾立刚,郭学志,王庆国.大鼠溃疡性结肠炎肝郁脾虚证模型的研究[J].北京中医药大学学报,1999,22(2)：21-23.
[22]顾立刚,郭学志,王庆国,等.疏肝健脾方对溃疡性结肠炎肝郁脾虚证大鼠结肠溃疡的影响[J].北京中医药大学学报,2000,23(4)：24-26.
[23]韩秋艳.肝郁脾虚证动物模型的建立[J].贵阳中医学院学报,2001,23(3)：59-61.
[24]张芳艳,毛新民,武鸿莉,等.肝郁脾虚型溃疡性结肠炎大鼠的免疫学研究[J].新疆医科大学学报,2004,27(4)：367.
[25]湖南医学院附一院中医基础理论研究室.肝郁脾虚的理论与实验研究[J].湖南医学院学报,1979,4(3)：131-143.
[26]郭振秋,赵晓威.肝纤宁对肝郁脾虚大鼠的保肝抗纤作用[J].湖南中医学院学报,1998,18(2)：10-12.
[27]李艳彦,谢鸣,陈禹,等.一种运用复合病因造模法复制大鼠肝邵脾虚证模型的研究[J].中国中医基础医学杂志,2006,12(6)：439-442.
[1]石红.中西医结合治疗反流性食管炎40例临床观察[J].甘肃中医,2009,22(7)：44-47.
[2]韩罡,韩莉.柴胡疏肝散治疗反流性食管炎[J].现代中西医结合杂志,2008,17(18)：2840.
[3]彭建新.中西医结合治疗变异型心绞痛38例临床观察[J].中医药导报,2009,15(3)：29-30.
[4]张新元.柴胡疏肝散加味治疗胸痹心痛的临床研究[J].中华实用中西医杂志,2008,21(20)：1550-1551.
[5]张端华.柴胡疏肝散在冠心病心绞痛中的应用[J].北京中医,1995,12(1)：21-22.
[6]秦双件.柴胡疏肝散合茵陈蒿汤化裁治疗慢性胆囊炎湿热血瘀证45例临床观察[J].中医药导报,2009,15(5)：33-34.
[7]李雪梅.中西医结合治疗慢性胃炎68例临床观察[J].江苏中医药,2009,41(6)： 37.
[8]王斌初.柴胡疏肝散加味治疗慢性浅表性胃炎208例总结[J].湖南中医杂志,2008,24(5)：11-12.
[9]李金臣,唐成定.柴、百、丹合剂治疗消化性溃疡38例[J].中国实用医药,2008,3(28)：104-105.
[10]潘丰满,黄江荣.柴胡疏肝散治疗非酒精性脂肪肝82例临床观察[J].时珍国医国药,2009,20(8)：2010-2011.
[11]王明华.柴胡疏肝散治疗肠易激综合征51例[J].中国实用医 药,2009,4(19)：172-173.
[12]杜生华.柴胡疏肝散治疗慢性胰腺炎120例报告[J].甘肃中医,2003,6(9)：15.
[13]刘建平.柴胡疏肝散合并氟西汀治疗抑郁症的临床观察[J].山西中医学院学报,2001,2(4)：31.
[14]郑建军,吴新华,李光明.柴胡疏肝散治疗肿瘤患者抑郁症63例[J].山东中医杂志,2001,21(9)：530.
[15]郑莉,王克勤.抑郁症中西医论治评析[J].包头医学院学报,2003,19(4)：355.
[16]周杰,罗仁瀚,黄云声.柴胡疏肝散加味治疗抑郁症37例临床研究[J].吉林中医药,2009,29(6)：477-478.
[17]屈沂.柴胡疏肝散加味治疗顽固性失眠50例[J].河南中医,2007,27(6)：68.
[18]尹晟.柴胡疏肝散加昧治疗失眠症64例临床观察[J].实用中医内科杂志,2008,22(10)：11-12.
[19]蔡秀巧.柴胡疏肝散加减治疗带状疱疹后遗神经痛32例[J].山东中医杂志,2007,26(9)：618-619.
[20]沈志忠.柴胡疏肝散加减治疗胃神经官能症35例[J].四川中医,1995,13(6)： 26.
[21]张兴正.柴胡疏肝散加减治疗瘿瘤120例[J].四川中医,2006,24(8)：55-56
[22]牛志世.柴胡疏肝汤治疗雷诺氏综合征31例疗效观察[J].实用中西医结合杂志,1993,6(7)：421.
[23]王秀春.柴胡疏肝散加减治疗乳腺增生病66例[J]. Journalof Medical Forum.2003,24 (11):19-21.
[24]华刚,孟静.柴胡疏肝散加减治疗乳腺增生120例[J].陕西中医,2005,26(3)： 214.
[25]严宇仙.柴胡疏肝散加减治疗不孕症[J].浙江中西医合杂志,2003,13(8)：509.
[26]王敬绪.柴胡疏肝散加减治疗输卵管不通3则[J].四川中医,1994,12(10)：43.
[27]于厚南.柴胡疏肝散加味治疗阳痿88例[J].四川中医,1996,14(10)：25.
[28]郑爱华,李家邦,蔡光先,等.柴胡疏肝散、四君子汤对肝郁、脾虚病人Th细胞分化信号蛋白PKC表达的影响[J].贵阳中医学院学报,2003,25(4)：14.
[29]陈松,李家邦,朱双罗,等.肝郁证T、B淋巴细胞活性改变及疏肝治疗影响的实验研究[J].湖南中医学院学报,2001,21(2)：7.
[30]陈梁,朱锦善,任建平.柴胡疏肝散对四氯化碳所致大鼠急性肝损伤的防治作用[J].中西医结合肝病杂志,2004,14(1)：42-43.
[31]熊振芳,朱清静.柴胡疏肝散对慢性束缚应激性肝郁证大鼠的影响[J].中国中西医结合消化杂志,2004,12(4)：220-221.
[32]朱清静,罗欣拉,熊振芳.柴胡疏肝散对慢性束缚应激性肝郁证大鼠下丘脑-垂体-肾上腺轴的调节作用[J].湖北中医杂志,2003,25(11)：7-8.
[33]陈煜辉,周莺.柴胡疏肝散抗抑郁作用的药理学实验研究[J].江西中医学院学报,2004,16(4)：59-60
[34]孙华英.加味四君子汤治疗小儿泄泻[J].湖北中医杂志,2009,32(7)：49.
[35]孙占杰.加味四君子汤治疗动力障碍型功能性消化不良60例[J].山西中医,2009,25(1)：16.
[36]李影华.四君子汤加减治疗脾胃虚弱型功能性消化不良的临床观察[J].北京中医药,2008,27(10)：806-807.
[37]杨洁.四君子汤配合四逆散治疗肠易激综合征临床研究[J].湖北中医杂志,2009,31(7)：16-17.
[38]施智严,施宝兴.柴芍四君子汤治疗慢性胃炎32例疗效观察[J].现代中西医结合杂志,2002,11(20)：1996-1997.
[39]罗仕娟,叶仕,黄志新.柴芍四君子汤加味治疗肝郁脾虚型溃疡结肠炎16例[J].中华实用中西医杂志,2009,22(8)：479-480.
[40]景慧,刘建邦.四君子汤加味治疗慢性结肠炎46例体会[J].新疆中医药,2002,20(3)：21.
[41]王松筠,王有力,杨明.四君子汤治疗胃粘膜脱垂30例[J].人民军医,1995,(1)：36-37.
[42]葛香芹.辨证治疗肝郁脾虚型慢性丙型肝炎30例[J].吉林中医药,2008,28(5)：341-342.
[43]华玉淑,唐汉庆.四君子汤加减治疗老年慢性支气管炎54例[J].长春中医药大学学报,2009,25(4)：517-518.
[44]朱鹏.四君子汤加味治疗2型糖尿病胃轻瘫30例[J].江西中医药,2009,39(304)：45.
[45]汪波,丁德秭.四君子汤合沙参麦冬汤加减配合化疗治疗中晚期非小细胞肺癌临床观察[J].世界中西医结合杂志,2009,4(8)：564-565.
[46]丁莉.四君子汤治疗乳痈35例[J].Journal of Medical Forum,2003,24 (7):47.
[47]陈宪忠.四君子汤合金匮肾气丸治疗小儿遗尿36例[J].河南中医,2007,27(9)：74.
[48]陆一君.四君子汤加味治疗小儿厌食症50例[J].福建中医药,2004,35(2)：33.
[49]吴冬芳.四君子汤加味治疗小儿厌食症78例[J].江苏中医药,2003,24(6)：34.
[50]吴宗德.四君子汤加减治疗小儿厌食症68例[J].四川中医,2003,21(12)：65.
[51]魏生有,李金宝,李润荣.四君子汤加味治疗小儿厌食症85例[J].新疆中医药,2005,23(6)：12.
[52]吴淑莲,黄晓利,张晓.葡萄糖酸锌颗粒与四君子汤加味联合治疗小儿反复呼吸道感染临床分析[J].医学研究杂志,2008,37(7)：66-68.
[53]陆国兰.四君子汤加味治疗小儿荨麻疹[J].中国民族民间医药杂志,2005,(73)： 97.
[54]陈宇海.四君子汤加味治疗儿童髋关节一过性滑膜炎63例[J].河北中医,2001,23(9)：664.
[55]赖意芬.四君子汤加味治疗小儿缺锌50例疗效观察[J].新中医,2002,34(1)： 20.
[56]唐月英,宋凯,曾屹生,等.加味四君子汤治疗脾气虚型常年性变应性鼻炎的临床疗效研究[J].中国中西医结合耳鼻咽喉科杂志,2008,16(6)：422-424.
[57]王文兰.四君子汤加味治疗慢性咽炎50例疗效观察[J].云南中医中药杂志,2002,23(6)：44.
[58]季宇彬,付永艳,胡晓梅,等.四君子汤对荷瘤小鼠红细胞免疫功能的影响[J].黑龙江商学院学报：自然科学版,2000,16(3)：1-4.
[59]李家邦,李立新.脾虚证与益气健脾治疗对T、B淋巴细胞活性影响的实验观察[J].湖南中医学院学报,2000,20(4)：9-10.
[60]章梅,夏天,吴少华,等.四君子汤对脾虚鼠脾细胞DNA合成的影响[J].贵阳中医学院学报,2000,22(3)：55-56.
[61]王洪海.四君子汤、柴疏四君汤、柴胡疏肝散作用于脾虚证大鼠模型的生物效应比较[D].北京：北京中医药大学,2007,6.
[62]王琚,高云芳,姚洋.不同剂量四君子汤对脾虚证小鼠消化和免疫功能的影响[J].中草药,2007,38(4)；558-564.
[63]张万岱,姚永莉,宋子刚.实验脾虚证组织中胃泌素及生长抑制素含量变化及其意义[J].现代消化病及内镜杂志,1998；3(4：)31-33.
[64]夏天,李刚,王宗仁,等.脾虚大鼠下丘脑-垂体-甲状腺轴功能的变化[J].安徽中医学院学报,2001,20(4)：42-45.
[65]温庆祥,张蕾,何俊仁,等.四君子汤对脾虚大鼠神经内分泌免疫网络功能的影响[J].中国中西医结合消化杂志,2005,13(2)：124-125.
[66]赵燕玲,夏天.大鼠脾虚证与胃窦及十二指肠组织5-HT细胞的关系及意义[J].安徽中医学院学报,2001,20(3)：87-89.
[67]修宗昌,李德新.脾虚证Ca2+-CaM信号系统的实验研究[J].中国医药学报,2002,17(12)：758-759.
[68]李传刚,舒晓宏,李墨林,等.四君子汤对膀胱癌小鼠抗氧化能力的影响[J].中医药学刊,2003,21(11)：1902-1903.
[69]李传刚,李墨林,舒晓宏,等.四君子汤对小鼠膀胱癌抗肿瘤作用的实验研究[J].中医药学刊,2004,22(2)：316-317.
[70]陈达理,黄涛.四君子汤对荷瘤小鼠抑瘤和诱导肿瘤细胞凋亡的实验研究[J].山东中医杂志,2004,23(4)：228-229.
[71]练慧,张正利.柴胡疏肝散合四君子汤加减治疗慢性萎缩性胃炎47例[J].上海中医药杂志,2006,40(5)：27-28.
[72]李艳彦,谢鸣,王洪海,等.肝郁脾虚证模型大鼠甲状腺轴的变化及柴疏四君汤的作用观察[J].中国中医基础医学杂志,2008,14(3)：191-195.
[1]谢鸣.方证相关的逻辑内涵及意义[J].北京中医药大学学报,2003,26(2)：11-12.
[2]费忠东.大柴胡汤现代方证研究[J].江苏中医药,2003,24(8)：43-45.
[3]谷松.四逆散方证相关理论问题的研究[J].中医药学刊,2006,24(1)：141-142.
[4]年莉,方玲,刘鸿雁.吴茱萸汤方证学研究[J].天津中医药,2004,21(1)：38-40.
[5]许得盛,沈自尹,王文健,等.右归饮、四君子汤、桃红四物汤调节肾虚、脾虚、血瘀证患者免疫功能的观察[J].中国中西医结合杂志,1999,19(12)： 712-714.
[6]管冬元,方肇勤,梁尚华,等.不同治法对大鼠肝癌相关作用的研究[J].上海中医药大学学报,2001,(3)：41-43.
[7]贺松其.肠激惹综合征从肝论治初探[J].深圳中西医结合杂志,2000,10(4)：55.
[8]王娅.柴胡疏肝散合四君子汤治疗胃痛50例[J].四川中医,2004,22(7)：62.
[9]王玉芬.胆汁返流性胃炎的中医研究述评[J].北京中医药大学学报,1998,21(1)： 9.
[10]朱清静,罗欣拉,熊振芳.柴胡疏肝散对慢性束缚应激性肝郁证大鼠下丘脑-垂体-肾上腺轴的调节作用[J].湖北中医杂志,2003,25(11)：7-9.
[11]彭成,张磊,张利,等.四逆散治疗功能性消化不良的实验研究[J].成都中医药大学学报,1999,22(1)：39-41.
[12]严灿.加减四逆散对慢性心理应激大鼠胸腺糖皮质激素受体作用的研究[J].中国中西医结合杂志.2002,22(9)：196-198.
[13]刘建平.柴胡疏肝散合并氟西汀治疗抑郁症的临床观察[J].山西中医学院学报,2001,2(4)：31-33.
[14]肖桂林,金益强,鄢东红,等.肝郁脾虚证实验诊断指标的研究[J].湖南中医学院学报,1998,18(2)：4.
[15]郑爱华,李家邦,蔡光先,等.肝气郁结证与脾气虚证的Th细胞分化中的相关性实验研究[J].中国医师杂志,2004,6(3)：357.
[1]罗国钧,罗海琳.慢性肝病肝郁脾虚证的研究进展[J].山西中医,2001,17(3)：57-59.
[2]李艳彦,谢鸣,陈禹,王洪海.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[3]黄柏炎,孙荭,曾洁铭.心理应激对正常人外周血T淋巴细胞体外活化表面分子表达的作用[J].中国病理生理杂志,2000,16(3)：45-47.
[4]孙莉,韩耀辉,赵彩虹.束缚应激对小鼠巨噬细胞吞噬功能的影响[J].中国行为医学科学,1999,8(1)：55-56.
[5]孙弼纲,田长经,沈鹰.中医“脾虚”证本质的临床探讨[J].安徽中医学院学报,1983,(3)：3-4.
[6]王济,顾立刚,王庆国,等.肝郁脾虚因素促进DEN诱发大鼠实验性肝癌的研究[J].中国中医药信息杂志,2003,10(1)：18-19.
[7]顾立刚,郭学志,王庆国.大鼠溃疡性结肠炎肝郁脾虚证动物模型的研究[J].北京中医药大学学报,1999,22(2)：21-23.
[8]Waldmann TA. The IL-2/IL-2 receptor system:a target for rational immune intervention [J]. Immunol Today,1993,14 (6):264-270.
[9]程伟,李春德.免疫生理学[M].上海：上海科学技术出版社,1993：185-187.
[10]龙振洲.医学免疫学[M].北京：人民卫生出版社,1997：48-52.
[1]杨鉴英,关茂会,李艳荣,等.慢性肝炎患者血清T3、T4变化与中医辨证分型的联系[J].中西医结合杂志,1986,6(6)：341-342.
[2]张俊富,崔丽安,王培生.慢性肝炎及肝硬化辨证分型与内分泌激素关系的探讨[J].中国中西医结合杂志,1991,11(3)：147-149.
[3]谭行华,肖真,杨克彬,等.慢性肝炎中医分型与内分泌激素的关系[J].中国中西医结合杂志,1995,15(10)：604-605.
[4]李艳彦,谢鸣,陈禹.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[5]刘振秀,王秀荣.促甲状腺激素释放激素对抗大鼠束缚应激的作用[J].中国医学科学院学报,1992,14(2)：118-121.
[6]李志强,陈津岩,何赞厚,等.四君子汤对脾虚证大鼠血清性激素和甲状腺激素水平的影响[J].河南中医,2008,28(3)：36-37.
[7]阎玥.疏肝、健脾、疏肝健脾方对肝郁脾虚证模型动物HPA轴调节作用的研究[C].北京中医药大学硕士研究生学位论文,2009：40-41.
[8]姚泰.生理学[M].北京：人民卫生出版社,2005：556-571.
[9]李艳彦.肝郁脾虚证的模型复制及相关方剂作用的生物学基础[D].北京中医药大学博士研究生学位论文,2006：96-98.
[1]严灿,邓中炎.从现代心理应激理论研究中医肝主疏泄功能[J].广州中医药大学学报,2000,17(3)：209-211.
[2]李艳彦,谢鸣,陈禹,等.肝郁脾虚证模型大鼠下丘脑-垂体-肾上腺皮质的变化[J].现代生物医学进展,2006,6(4)：10-15.
[3]胡宜,王静舒译.HPA轴-丘脑下部-垂体-肾上腺皮质的最新研究进展[J].日本医学介绍,2003,24(1)：46.
[4]王子梅.ACTH激素分泌调节新进展[J].国外医学内分泌学分册,1994,14(4)：
[1]陈国祯.肝郁脾虚证的本质探讨[J].中西医结合杂志,1985,5(12)：723.
[2]李艳彦,谢鸣,陈禹.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[3]周吕,柯美云.神经胃肠病学与动力基础与临床[M].北京：科学出版社,2005：83.
[4]杨大明.胃蛋白酶与消化性溃疡[J].国外医学：内科学分册,1990,17(5)：193-196.
[5]李艳彦.肝郁脾虚证的模型复制及相关方剂作用的生物学基础[D].北京中医药大学博士研究生学位论文,2006：96-98.
[6]须育方.生物化学教程[M].北京：北京工业大学出版社,1988,123～126.
[1]李艳彦,谢鸣,陈禹.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[2]王鸿儒.血液流变学[M].北京：北京医科大学、中国协和医科大学联合出版社,1997：19-33.
[1]李艳彦,谢鸣,陈禹.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[2]钟小兰,吕志平,钱令嘉,等.肝郁证模型大鼠血清蛋白组的差异表达研究[J].中华中医药杂志,2006,21(7)：399-401.
[3]罗云坚,修宗昌,黄穗平,等.脾气虚证免疫相关基因组学机制初探[J].中国中西医结合杂志,2005,25(4)：313.
[4]Ntambi JM. Regulation of stearoy 12 CoA desaturase by polyunsaturated fat2ty acids and cholesterol [J]. J Lipid Res,1999,40(9):1549-2558.
[5]刘泽军.乳酸脱氢酶A亚单位基因变异与临床[J].日本医学介绍,1998,19(2)：89-90.
[6]李刚强,周海亚,朱瑞.乳腺癌组织中Bubl和p53的表达与意义[J].中华肿瘤防治杂志,2007,14(9)：683-685.
[7]李刚强,曹金龙.乳腺癌中Bubl蛋白的表达及临床意义[J].肿瘤,2006,26(8)：758-760.
[8]Shigeishi H, Yoneda S, Taki M, et al. Correlation of humanBubl expression with tumor-proliferating activity in salivarygland tumors [J]. Oncol Rep,2006,15 (4):933-938.
[9]洪天配.关注胰岛素原／总胰岛素比值在胰岛β细胞功能评价中的意义[J].中国糖尿病杂志,2009,17(5)：321-32
[2]吴圣贤,方素钦,王映辉,等.中医肝郁脾虚证症状分布和特征专家问卷调查研究[J].北京中医药大学学报,2007,30(12)：854-856.
[3]金益强,胡随瑜,张翔,等.中医不同证候血浆去甲肾上腺素和肾上腺素及植物神经功能的研究[J].中西医结合杂志,1998,18(11)：655-657.
[4]肖桂林,金益强,鄢东红,等.单纯脾气虚证与肝郁脾虚证内在差别的实验研究[J].江西中医学院学报,2000,12(1)：35.
[5]李家邦,王勇华.肝郁脾虚证患者植物神经功能障碍的特征[J].湖南医学院学报,1985,10(1)：63-66.
[6]杨兴中,刘伟英.慢性乙型肝炎中医辨证分型与客观检测指标关系的探讨[J].山西中医,1991,7(2)：9-11.
[7]鲍逊,杨珍珠,范纯武,等.慢性肝病中医辨证分型的生化和免疫学基础的初步探讨[J].中医杂志,1982,23(7)：516-519.
[8]龚远明,张杜郎,张仲苓.病毒性肝炎的中医分型与免疫关系[J].陕西中医,1993,14(7)：328-329.
[9]楼孝惠,陈智,黄茵,等.慢性乙型肝炎中医证型与IL-2,IL-10,IL-12,IFN-r水平的关系初探[J].中西医结合肝病杂志,2001,11(5)：282.
[10]周虎,周萍,俞庆福.慢性病毒性肝炎T淋巴细胞亚群、免疫球蛋白变化与中医证候关系探讨[J].江西中医学院学报,2001,13(2)：49.
[11]郑洪新,李德新,赵明山,等.肝郁脾虚证消化性溃疡的神经免疫学研[J].中国中医基础医学杂志,1996,2(3)：27.
[12]杨英,关茂会,李艳荣,等.慢性肝炎患者血清T3、T4变化与中医辨证分型的联系[J].中西医结合杂志,1986,6(6)：341.
[13]谭行华,肖真,杨克彬,等.慢性肝炎中医分型与内分泌激素的关系[J].中西医结合杂志,1995,15(10)：604-605.
[14]金益强,刘璜英,李学文.227例肝郁脾虚证患者小肠吸收功能障碍的分析[J].湖南医学院学报,1985,10(1)：38-39.
[15]张俊富,崔丽安.慢性肝炎及肝硬化辨证分型与血清肝纤维化指标的关系[J].中西医结合肝病杂志,1995,5(4)：10-11.
[16]杨兴中,刘伟英.慢性乙型肝炎中医辨证分型与客观检测指标关系的探[J].山西中医,1991,7(2)：9-11.
[17]陈礼华,陈燕,杨帆,等.慢性肝炎的辨证分型与血清肝纤维化指标的关系[J].中西医结合肝病杂志,1997,7(3)：165-166.
[18]任平,黄熙,李双庆,等.脾气虚、肝郁脾虚及胃实热证患者阿魏酸药代动力学特征比较[J].中西医结合学报,2006,4(2)：147-151.
[19]邝元亮,颜文明.肝郁脾虚证血液流变性之初步研究[J].湖南中医学院学报,1989,9(2)：101.
[20]陈国祯.肝郁脾虚证的本质探讨[J].中西医结合杂志,1985,5(12)：732-735.
[21]顾立刚,郭学志,王庆国.大鼠溃疡性结肠炎肝郁脾虚证模型的研究[J].北京中医药大学学报,1999,22(2)：21-23.
[22]顾立刚,郭学志,王庆国,等.疏肝健脾方对溃疡性结肠炎肝郁脾虚证大鼠结肠溃疡的影响[J].北京中医药大学学报,2000,23(4)：24-26.
[23]韩秋艳.肝郁脾虚证动物模型的建立[J].贵阳中医学院学报,2001,23(3)：59-61.
[24]张芳艳,毛新民,武鸿莉,等.肝郁脾虚型溃疡性结肠炎大鼠的免疫学研究[J].新疆医科大学学报,2004,27(4)：367.
[25]湖南医学院附一院中医基础理论研究室.肝郁脾虚的理论与实验研究[J].湖南医学院学报,1979,4(3)：131-143.
[26]郭振秋,赵晓威.肝纤宁对肝郁脾虚大鼠的保肝抗纤作用[J].湖南中医学院学报,1998,18(2)：10-12.
[27]李艳彦,谢鸣,陈禹,等.一种运用复合病因造模法复制大鼠肝邵脾虚证模型的研究[J].中国中医基础医学杂志,2006,12(6)：439-442.
[1]石红.中西医结合治疗反流性食管炎40例临床观察[J].甘肃中医,2009,22(7)：44-47.
[2]韩罡,韩莉.柴胡疏肝散治疗反流性食管炎[J].现代中西医结合杂志,2008,17(18)：2840.
[3]彭建新.中西医结合治疗变异型心绞痛38例临床观察[J].中医药导报,2009,15(3)：29-30.
[4]张新元.柴胡疏肝散加味治疗胸痹心痛的临床研究[J].中华实用中西医杂志,2008,21(20)：1550-1551.
[5]张端华.柴胡疏肝散在冠心病心绞痛中的应用[J].北京中医,1995,12(1)：21-22.
[6]秦双件.柴胡疏肝散合茵陈蒿汤化裁治疗慢性胆囊炎湿热血瘀证45例临床观察[J].中医药导报,2009,15(5)：33-34.
[7]李雪梅.中西医结合治疗慢性胃炎68例临床观察[J].江苏中医药,2009,41(6)： 37.
[8]王斌初.柴胡疏肝散加味治疗慢性浅表性胃炎208例总结[J].湖南中医杂志,2008,24(5)：11-12.
[9]李金臣,唐成定.柴、百、丹合剂治疗消化性溃疡38例[J].中国实用医药,2008,3(28)：104-105.
[10]潘丰满,黄江荣.柴胡疏肝散治疗非酒精性脂肪肝82例临床观察[J].时珍国医国药,2009,20(8)：2010-2011.
[11]王明华.柴胡疏肝散治疗肠易激综合征51例[J].中国实用医 药,2009,4(19)：172-173.
[12]杜生华.柴胡疏肝散治疗慢性胰腺炎120例报告[J].甘肃中医,2003,6(9)：15.
[13]刘建平.柴胡疏肝散合并氟西汀治疗抑郁症的临床观察[J].山西中医学院学报,2001,2(4)：31.
[14]郑建军,吴新华,李光明.柴胡疏肝散治疗肿瘤患者抑郁症63例[J].山东中医杂志,2001,21(9)：530.
[15]郑莉,王克勤.抑郁症中西医论治评析[J].包头医学院学报,2003,19(4)：355.
[16]周杰,罗仁瀚,黄云声.柴胡疏肝散加味治疗抑郁症37例临床研究[J].吉林中医药,2009,29(6)：477-478.
[17]屈沂.柴胡疏肝散加味治疗顽固性失眠50例[J].河南中医,2007,27(6)：68.
[18]尹晟.柴胡疏肝散加昧治疗失眠症64例临床观察[J].实用中医内科杂志,2008,22(10)：11-12.
[19]蔡秀巧.柴胡疏肝散加减治疗带状疱疹后遗神经痛32例[J].山东中医杂志,2007,26(9)：618-619.
[20]沈志忠.柴胡疏肝散加减治疗胃神经官能症35例[J].四川中医,1995,13(6)： 26.
[21]张兴正.柴胡疏肝散加减治疗瘿瘤120例[J].四川中医,2006,24(8)：55-56
[22]牛志世.柴胡疏肝汤治疗雷诺氏综合征31例疗效观察[J].实用中西医结合杂志,1993,6(7)：421.
[23]王秀春.柴胡疏肝散加减治疗乳腺增生病66例[J]. Journalof Medical Forum.2003,24 (11):19-21.
[24]华刚,孟静.柴胡疏肝散加减治疗乳腺增生120例[J].陕西中医,2005,26(3)： 214.
[25]严宇仙.柴胡疏肝散加减治疗不孕症[J].浙江中西医合杂志,2003,13(8)：509.
[26]王敬绪.柴胡疏肝散加减治疗输卵管不通3则[J].四川中医,1994,12(10)：43.
[27]于厚南.柴胡疏肝散加味治疗阳痿88例[J].四川中医,1996,14(10)：25.
[28]郑爱华,李家邦,蔡光先,等.柴胡疏肝散、四君子汤对肝郁、脾虚病人Th细胞分化信号蛋白PKC表达的影响[J].贵阳中医学院学报,2003,25(4)：14.
[29]陈松,李家邦,朱双罗,等.肝郁证T、B淋巴细胞活性改变及疏肝治疗影响的实验研究[J].湖南中医学院学报,2001,21(2)：7.
[30]陈梁,朱锦善,任建平.柴胡疏肝散对四氯化碳所致大鼠急性肝损伤的防治作用[J].中西医结合肝病杂志,2004,14(1)：42-43.
[31]熊振芳,朱清静.柴胡疏肝散对慢性束缚应激性肝郁证大鼠的影响[J].中国中西医结合消化杂志,2004,12(4)：220-221.
[32]朱清静,罗欣拉,熊振芳.柴胡疏肝散对慢性束缚应激性肝郁证大鼠下丘脑-垂体-肾上腺轴的调节作用[J].湖北中医杂志,2003,25(11)：7-8.
[33]陈煜辉,周莺.柴胡疏肝散抗抑郁作用的药理学实验研究[J].江西中医学院学报,2004,16(4)：59-60
[34]孙华英.加味四君子汤治疗小儿泄泻[J].湖北中医杂志,2009,32(7)：49.
[35]孙占杰.加味四君子汤治疗动力障碍型功能性消化不良60例[J].山西中医,2009,25(1)：16.
[36]李影华.四君子汤加减治疗脾胃虚弱型功能性消化不良的临床观察[J].北京中医药,2008,27(10)：806-807.
[37]杨洁.四君子汤配合四逆散治疗肠易激综合征临床研究[J].湖北中医杂志,2009,31(7)：16-17.
[38]施智严,施宝兴.柴芍四君子汤治疗慢性胃炎32例疗效观察[J].现代中西医结合杂志,2002,11(20)：1996-1997.
[39]罗仕娟,叶仕,黄志新.柴芍四君子汤加味治疗肝郁脾虚型溃疡结肠炎16例[J].中华实用中西医杂志,2009,22(8)：479-480.
[40]景慧,刘建邦.四君子汤加味治疗慢性结肠炎46例体会[J].新疆中医药,2002,20(3)：21.
[41]王松筠,王有力,杨明.四君子汤治疗胃粘膜脱垂30例[J].人民军医,1995,(1)：36-37.
[42]葛香芹.辨证治疗肝郁脾虚型慢性丙型肝炎30例[J].吉林中医药,2008,28(5)：341-342.
[43]华玉淑,唐汉庆.四君子汤加减治疗老年慢性支气管炎54例[J].长春中医药大学学报,2009,25(4)：517-518.
[44]朱鹏.四君子汤加味治疗2型糖尿病胃轻瘫30例[J].江西中医药,2009,39(304)：45.
[45]汪波,丁德秭.四君子汤合沙参麦冬汤加减配合化疗治疗中晚期非小细胞肺癌临床观察[J].世界中西医结合杂志,2009,4(8)：564-565.
[46]丁莉.四君子汤治疗乳痈35例[J].Journal of Medical Forum,2003,24 (7):47.
[47]陈宪忠.四君子汤合金匮肾气丸治疗小儿遗尿36例[J].河南中医,2007,27(9)：74.
[48]陆一君.四君子汤加味治疗小儿厌食症50例[J].福建中医药,2004,35(2)：33.
[49]吴冬芳.四君子汤加味治疗小儿厌食症78例[J].江苏中医药,2003,24(6)：34.
[50]吴宗德.四君子汤加减治疗小儿厌食症68例[J].四川中医,2003,21(12)：65.
[51]魏生有,李金宝,李润荣.四君子汤加味治疗小儿厌食症85例[J].新疆中医药,2005,23(6)：12.
[52]吴淑莲,黄晓利,张晓.葡萄糖酸锌颗粒与四君子汤加味联合治疗小儿反复呼吸道感染临床分析[J].医学研究杂志,2008,37(7)：66-68.
[53]陆国兰.四君子汤加味治疗小儿荨麻疹[J].中国民族民间医药杂志,2005,(73)： 97.
[54]陈宇海.四君子汤加味治疗儿童髋关节一过性滑膜炎63例[J].河北中医,2001,23(9)：664.
[55]赖意芬.四君子汤加味治疗小儿缺锌50例疗效观察[J].新中医,2002,34(1)： 20.
[56]唐月英,宋凯,曾屹生,等.加味四君子汤治疗脾气虚型常年性变应性鼻炎的临床疗效研究[J].中国中西医结合耳鼻咽喉科杂志,2008,16(6)：422-424.
[57]王文兰.四君子汤加味治疗慢性咽炎50例疗效观察[J].云南中医中药杂志,2002,23(6)：44.
[58]季宇彬,付永艳,胡晓梅,等.四君子汤对荷瘤小鼠红细胞免疫功能的影响[J].黑龙江商学院学报：自然科学版,2000,16(3)：1-4.
[59]李家邦,李立新.脾虚证与益气健脾治疗对T、B淋巴细胞活性影响的实验观察[J].湖南中医学院学报,2000,20(4)：9-10.
[60]章梅,夏天,吴少华,等.四君子汤对脾虚鼠脾细胞DNA合成的影响[J].贵阳中医学院学报,2000,22(3)：55-56.
[61]王洪海.四君子汤、柴疏四君汤、柴胡疏肝散作用于脾虚证大鼠模型的生物效应比较[D].北京：北京中医药大学,2007,6.
[62]王琚,高云芳,姚洋.不同剂量四君子汤对脾虚证小鼠消化和免疫功能的影响[J].中草药,2007,38(4)；558-564.
[63]张万岱,姚永莉,宋子刚.实验脾虚证组织中胃泌素及生长抑制素含量变化及其意义[J].现代消化病及内镜杂志,1998；3(4：)31-33.
[64]夏天,李刚,王宗仁,等.脾虚大鼠下丘脑-垂体-甲状腺轴功能的变化[J].安徽中医学院学报,2001,20(4)：42-45.
[65]温庆祥,张蕾,何俊仁,等.四君子汤对脾虚大鼠神经内分泌免疫网络功能的影响[J].中国中西医结合消化杂志,2005,13(2)：124-125.
[66]赵燕玲,夏天.大鼠脾虚证与胃窦及十二指肠组织5-HT细胞的关系及意义[J].安徽中医学院学报,2001,20(3)：87-89.
[67]修宗昌,李德新.脾虚证Ca2+-CaM信号系统的实验研究[J].中国医药学报,2002,17(12)：758-759.
[68]李传刚,舒晓宏,李墨林,等.四君子汤对膀胱癌小鼠抗氧化能力的影响[J].中医药学刊,2003,21(11)：1902-1903.
[69]李传刚,李墨林,舒晓宏,等.四君子汤对小鼠膀胱癌抗肿瘤作用的实验研究[J].中医药学刊,2004,22(2)：316-317.
[70]陈达理,黄涛.四君子汤对荷瘤小鼠抑瘤和诱导肿瘤细胞凋亡的实验研究[J].山东中医杂志,2004,23(4)：228-229.
[71]练慧,张正利.柴胡疏肝散合四君子汤加减治疗慢性萎缩性胃炎47例[J].上海中医药杂志,2006,40(5)：27-28.
[72]李艳彦,谢鸣,王洪海,等.肝郁脾虚证模型大鼠甲状腺轴的变化及柴疏四君汤的作用观察[J].中国中医基础医学杂志,2008,14(3)：191-195.
[1]谢鸣.方证相关的逻辑内涵及意义[J].北京中医药大学学报,2003,26(2)：11-12.
[2]费忠东.大柴胡汤现代方证研究[J].江苏中医药,2003,24(8)：43-45.
[3]谷松.四逆散方证相关理论问题的研究[J].中医药学刊,2006,24(1)：141-142.
[4]年莉,方玲,刘鸿雁.吴茱萸汤方证学研究[J].天津中医药,2004,21(1)：38-40.
[5]许得盛,沈自尹,王文健,等.右归饮、四君子汤、桃红四物汤调节肾虚、脾虚、血瘀证患者免疫功能的观察[J].中国中西医结合杂志,1999,19(12)： 712-714.
[6]管冬元,方肇勤,梁尚华,等.不同治法对大鼠肝癌相关作用的研究[J].上海中医药大学学报,2001,(3)：41-43.
[7]贺松其.肠激惹综合征从肝论治初探[J].深圳中西医结合杂志,2000,10(4)：55.
[8]王娅.柴胡疏肝散合四君子汤治疗胃痛50例[J].四川中医,2004,22(7)：62.
[9]王玉芬.胆汁返流性胃炎的中医研究述评[J].北京中医药大学学报,1998,21(1)： 9.
[10]朱清静,罗欣拉,熊振芳.柴胡疏肝散对慢性束缚应激性肝郁证大鼠下丘脑-垂体-肾上腺轴的调节作用[J].湖北中医杂志,2003,25(11)：7-9.
[11]彭成,张磊,张利,等.四逆散治疗功能性消化不良的实验研究[J].成都中医药大学学报,1999,22(1)：39-41.
[12]严灿.加减四逆散对慢性心理应激大鼠胸腺糖皮质激素受体作用的研究[J].中国中西医结合杂志.2002,22(9)：196-198.
[13]刘建平.柴胡疏肝散合并氟西汀治疗抑郁症的临床观察[J].山西中医学院学报,2001,2(4)：31-33.
[14]肖桂林,金益强,鄢东红,等.肝郁脾虚证实验诊断指标的研究[J].湖南中医学院学报,1998,18(2)：4.
[15]郑爱华,李家邦,蔡光先,等.肝气郁结证与脾气虚证的Th细胞分化中的相关性实验研究[J].中国医师杂志,2004,6(3)：357.
[1]罗国钧,罗海琳.慢性肝病肝郁脾虚证的研究进展[J].山西中医,2001,17(3)：57-59.
[2]李艳彦,谢鸣,陈禹,王洪海.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[3]黄柏炎,孙荭,曾洁铭.心理应激对正常人外周血T淋巴细胞体外活化表面分子表达的作用[J].中国病理生理杂志,2000,16(3)：45-47.
[4]孙莉,韩耀辉,赵彩虹.束缚应激对小鼠巨噬细胞吞噬功能的影响[J].中国行为医学科学,1999,8(1)：55-56.
[5]孙弼纲,田长经,沈鹰.中医“脾虚”证本质的临床探讨[J].安徽中医学院学报,1983,(3)：3-4.
[6]王济,顾立刚,王庆国,等.肝郁脾虚因素促进DEN诱发大鼠实验性肝癌的研究[J].中国中医药信息杂志,2003,10(1)：18-19.
[7]顾立刚,郭学志,王庆国.大鼠溃疡性结肠炎肝郁脾虚证动物模型的研究[J].北京中医药大学学报,1999,22(2)：21-23.
[8]Waldmann TA. The IL-2/IL-2 receptor system:a target for rational immune intervention [J]. Immunol Today,1993,14 (6):264-270.
[9]程伟,李春德.免疫生理学[M].上海：上海科学技术出版社,1993：185-187.
[10]龙振洲.医学免疫学[M].北京：人民卫生出版社,1997：48-52.
[1]杨鉴英,关茂会,李艳荣,等.慢性肝炎患者血清T3、T4变化与中医辨证分型的联系[J].中西医结合杂志,1986,6(6)：341-342.
[2]张俊富,崔丽安,王培生.慢性肝炎及肝硬化辨证分型与内分泌激素关系的探讨[J].中国中西医结合杂志,1991,11(3)：147-149.
[3]谭行华,肖真,杨克彬,等.慢性肝炎中医分型与内分泌激素的关系[J].中国中西医结合杂志,1995,15(10)：604-605.
[4]李艳彦,谢鸣,陈禹.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[5]刘振秀,王秀荣.促甲状腺激素释放激素对抗大鼠束缚应激的作用[J].中国医学科学院学报,1992,14(2)：118-121.
[6]李志强,陈津岩,何赞厚,等.四君子汤对脾虚证大鼠血清性激素和甲状腺激素水平的影响[J].河南中医,2008,28(3)：36-37.
[7]阎玥.疏肝、健脾、疏肝健脾方对肝郁脾虚证模型动物HPA轴调节作用的研究[C].北京中医药大学硕士研究生学位论文,2009：40-41.
[8]姚泰.生理学[M].北京：人民卫生出版社,2005：556-571.
[9]李艳彦.肝郁脾虚证的模型复制及相关方剂作用的生物学基础[D].北京中医药大学博士研究生学位论文,2006：96-98.
[1]严灿,邓中炎.从现代心理应激理论研究中医肝主疏泄功能[J].广州中医药大学学报,2000,17(3)：209-211.
[2]李艳彦,谢鸣,陈禹,等.肝郁脾虚证模型大鼠下丘脑-垂体-肾上腺皮质的变化[J].现代生物医学进展,2006,6(4)：10-15.
[3]胡宜,王静舒译.HPA轴-丘脑下部-垂体-肾上腺皮质的最新研究进展[J].日本医学介绍,2003,24(1)：46.
[4]王子梅.ACTH激素分泌调节新进展[J].国外医学内分泌学分册,1994,14(4)：
[1]陈国祯.肝郁脾虚证的本质探讨[J].中西医结合杂志,1985,5(12)：723.
[2]李艳彦,谢鸣,陈禹.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[3]周吕,柯美云.神经胃肠病学与动力基础与临床[M].北京：科学出版社,2005：83.
[4]杨大明.胃蛋白酶与消化性溃疡[J].国外医学：内科学分册,1990,17(5)：193-196.
[5]李艳彦.肝郁脾虚证的模型复制及相关方剂作用的生物学基础[D].北京中医药大学博士研究生学位论文,2006：96-98.
[6]须育方.生物化学教程[M].北京：北京工业大学出版社,1988,123～126.
[1]李艳彦,谢鸣,陈禹.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[2]王鸿儒.血液流变学[M].北京：北京医科大学、中国协和医科大学联合出版社,1997：19-33.
[1]李艳彦,谢鸣,陈禹.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志(原中国医药学报),2006,21(7)：428-429.
[2]钟小兰,吕志平,钱令嘉,等.肝郁证模型大鼠血清蛋白组的差异表达研究[J].中华中医药杂志,2006,21(7)：399-401.
[3]罗云坚,修宗昌,黄穗平,等.脾气虚证免疫相关基因组学机制初探[J].中国中西医结合杂志,2005,25(4)：313.
[4]Ntambi JM. Regulation of stearoy 12 CoA desaturase by polyunsaturated fat2ty acids and cholesterol [J]. J Lipid Res,1999,40(9):1549-2558.
[5]刘泽军.乳酸脱氢酶A亚单位基因变异与临床[J].日本医学介绍,1998,19(2)：89-90.
[6]李刚强,周海亚,朱瑞.乳腺癌组织中Bubl和p53的表达与意义[J].中华肿瘤防治杂志,2007,14(9)：683-685.
[7]李刚强,曹金龙.乳腺癌中Bubl蛋白的表达及临床意义[J].肿瘤,2006,26(8)：758-760.
[8]Shigeishi H, Yoneda S, Taki M, et al. Correlation of humanBubl expression with tumor-proliferating activity in salivarygland tumors [J]. Oncol Rep,2006,15 (4):933-938.
[9]洪天配.关注胰岛素原／总胰岛素比值在胰岛β细胞功能评价中的意义[J].中国糖尿病杂志,2009,17(5)：321-32